Dr. Reddy's Laboratories Limited

NYSE:RDY

Drug Manufacturers - Specialty & Generic

Healthcare
$14.98 -1.13%

-$0.15 today

Market cap
$12.48B
Beta
0.26
P/E (TTM)
24.7
EPS (TTM)
$51.40
Dividend yield
0.63%
52W Low $12.19High $15.71

Volume 1.79M

Average 2.39M

RDY Debt Repayment

Cash used to repay borrowings during the period.

Dr. Reddy's Laboratories LimitedNYSE: RDY

Debt Repayment · Q2 FY2027 · quarter ended Sep 2026

Debt repayment dips below year-ago levels

Q2 FY2027 debt repayment of ₹698.07M fell 70.5% year over year, behind the +932.0% change in trailing-twelve-month debt repayment.

Context

  • Debt repayment amounted to 6.0% of revenue in FY2026, down 1.1 pp from a year earlier.
  • Debt repayment increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -70.5% toward the trailing-twelve-month pace of +932.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
₹698.07M+112.0% QoQ
Last fiscal yearMar 2026
₹21.31B-8.1% YoY
LTMSep 2026
₹12.6B+932.0% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-70.5%——
1 year-8.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

INR · from the cash flow

Latest · FY2026
21.31B INR
Year-over-year change
-8.1%
4-year CAGR
+67.1%

Debt Repayment vs competitors

How RDY compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +932.0% is the highest of 8, against a peer median of -103.7%.
  • Debt repayment amounts to 3.8% of revenue for RDY, versus a peer median of 4.7%.
RDY Competitors
Debt Repayment for RDY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹12.6B INR+932.0%—3.8%
HLNHaleon plcFY2025£1.28B GBP-315.8%—11.6%
BHCBausch Health Companies Inc.LTM Jun 2026$1.01B USD-591.3%-13.7%9.3%
VTRSViatris Inc.LTM Jun 2026$923.5M USD-68.3%—6.3%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$475.36M USD-76.8%+9.8%2.7%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$146.75M USD+182.6%—4.7%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$12.19M USD-103.7%+50.2%1.3%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$1.63M USD-121.0%—0.2%
Peer median (excluding RDY) —-103.7%+9.8%4.7%

Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

INR
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income23.57B45.07B55.68B57.25B45.09B
Depreciation & Amortization11.82B12.64B14.84B17.06B21.68B
Deferred Income Tax8.73B15.3B16.19B19.54B0
Stock-Based Compensation592M397M407M424M0
Change in Working Capital(13.91B)(7.86B)(20.18B)(29.99B)(12.24B)
Accounts Receivables(17.01B)(5.75B)(8.05B)(10.28B)(7.07B)
Inventory(5.33B)(2.65B)(18.45B)(12.75B)(9.05B)
Accounts Payables17.01B0002.94B
Other Working Capital(8.59B)551M6.32B(6.95B)943.83M
Other Non-Cash Items(2.69B)(6.67B)(21.5B)(17.85B)2.12B
Operating Cash Flow28.11B58.88B45.43B46.43B56.65B
Capital Expenditures(19.05B)(18.87B)(27.44B)(34.4B)(24.54B)
Acquisitions (Net)(326M)0(12M)(53.41B)(2.99B)
Purchases of Investments(88.97B)(136.17B)(145.49B)(254.46B)(49.21B)
Sales of Investments77.77B112.81B129.78B279.58B20.63B
Other Investing Activities4.19B(6.68B)(8.16B)(2.28B)1.47B
Investing Cash Flow(26.39B)(41.37B)(40.28B)(58.08B)(70.53B)
Debt Repayment2.74B(20.4B)4.35B23.2B21.31B
Common Stock Issued334M368M805M193M417.73M
Common Stock Repurchased000(1.39B)0
Dividends Paid(4.15B)(4.98B)(6.65B)(6.66B)(7.01B)
Other Financing Activities(1.35B)(1.85B)(2.27B)3.57B(1.33B)
Financing Cash Flow(2.42B)(26.86B)(3.76B)18.91B13.4B
Effect of Forex Changes733M286M(59M)224M(383.41M)
Net Change in Cash32M(9.07B)1.33B7.49B(875.84M)
Free Cash Flow9.06B40.01B18B12.03B32.1B

Dr. Reddy's Laboratories Limited

NYSE:RDY

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.